Transcription of hepatitis B Virus (HBV), an important risk factor of hepatocellular carcinoma (HCC), is controlled by cellular transcription activators including some of the cellular signaling targets. Consequently, HBV transcription rate changes in response to the cellular physiological conditions. In this report we investigated HBV gene expression and the role of physiological levels of the viral X protein (pX) under cisplatin induced genotoxic stress. We show that under these conditions the RNA level of an HBV mutant which does not express pX is sharply reduced. Studies revealed that transcription repression is responsible for the observed reduction in HBV RNA level. Repression of HBV transcription was obtained only in the p53 pro®cient cells. Furthermore, HBV transcription rate is recovered by the cotransfected p53 dominant negative plasmid, indicating that p53 is directly responsible for HBV transcription repression. Unexpectedly, p73, the recent p53 homologue, does not repress but rather activates HBV transcription. Interestingly, pX produced either by the HBV genome or by a cotransfected plasmid, relieves the p53 mediated repression. Collectively, these results attribute a physiological role to p53-inactivation by pX, and explain how pX may support HCC development.
Introduction
HBV is the prototype of the hepadnaviruses. HBV is a primarily hepatotropic, enveloped DNA virus bearing a tiny genome that replicates via reverse-transcription. HBV transcription is largely regulated at the level of initiation. RNA processing seems to play a minor role. The viral genome contains enhancer elements that regulate viral gene expression in liver cells (Shaul et al., 1985; Jameel and Siddiqui 1986; Honigwachs et al., 1989; Yee 1989) . Upon infection or DNA transfection, four major viral transcripts are detected. The largest 3.5 Kb RNA is composed of two preCore (pcRNA) and preGenomic (pgRNA) mRNAs, that program the synthesis of HBeAg and HBcAg, respectively. pgRNA also serves as a template for reverse-transcription to synthesize the viral DNA genome. Two other transcripts, 2.3 to 2.1 Kb mRNAs direct the production of the S, PreS1, PreS2 surface antigens. The smallest known transcript is the 0.7 Kb X mRNA, believed to be responsible for X protein production.
Due to the lack of HBV infection system, the study of HBV transcription regulation is in large incomplete. A partial solution to this technical problem came from the study of HBV transgenic mice, active in HBV transcription and replication (Guidotti et al., 1995) . These animals express the same set of transcripts detected in infected individuals. However, this experimental approach can not answer the questions of`if' and`how' the dierent HBV transcripts are differentially regulated along the virus life cycle. Furthermore, as in HBV transgenic animals, when the active viral DNA template is integrated into the mouse genome, the pattern of gene expression only partially resembles the genuine viral infection, where the DNA template is mainly episomal. In this study we employed the transient transfection technique to follow HBV gene expression. This experimental approach, although not mimicking natural infection processes, does give rise to the production of the expected viral transcripts from an episomal DNA template.
Transcription of the HBV genes is regulated by multiple cellular transcription factors and activators. Some of these factors are known to be activated by the cellular signaling and therefore, are likely to support HBV transcription under unstable cellular external milieu (Faktor et al., 1990; Ohno et al., 1997; Raney et al., 1997) . In addition pX, the viral regulator protein, plays a role in stimulating some of the signaling pathways (Luber et al., 1993; Natoli et al., 1994; Doria et al., 1995; Benn et al., 1996; Su and Schneider 1996; Klein and Schneider 1997) . HBV gene expression is also highly aected by cytokines (Guidotti et al., 1996) possibly to escape the host immune surveillance. Thus, one promising way to investigate the mechanisms of HBV gene expression and the role of pX in HBV life cycle is to expose the host-cells to dierent stimuli and to monitor the production of the HBV transcripts. In this report we investigated HBV behavior under stress condition induced by a genotoxic drug.
Exposing mammalian cells to DNA-damaging agents often causes blocks in cell growth and sometime leads to cell death. The mammalian cellular response to genotoxic stress is a complex process involving many known and probably many as yet unknown genes. Cisplatin is a genotoxic agent that is widely used in the treatment of a variety of human tumors. Cisplatin treatment of cells leads to DNA damage by the formation of DNA interstrand crosslinks (Roberts and Friedlos, 1981) . Genotoxic treatment, including cisplatin, induces p53 over production (Fritsche et al., 1993) . Previously, we have reported that p53 binds, in a sequence speci®c manner, to the 5' portion of the HBV enhancer and represses its activity (Ori et al., 1998) . This fact and the reported interplay between p53 and pX, suggested an HBV speci®c response to genotoxic stress. Here we show that HBV transcription is repressed in cisplatin treated cells in a p53-dependent manner. Furthermore, we found that the viral encoded transcription coactivator, pX, can abrogate this p53-mediated repression. These ®ndings attribute possible roles to pX in HBV life cycle and in HCC development.
Results

Repression of HBV gene expression upon genotoxic stress
To test the behavior of HBV under genotoxic stress, cells were transfected with HBV-DNA and treated with cisplatin, a DNA damaging agent. For these experiments HepG2 cells were used as they are known to contain wt p53 (Bressac et al., 1990; Hosono et al., 1991) and to support both HBV gene expression and replication (Sells et al., 1987; Sureau et al., 1986) . The expected HBV dierent transcripts are easily detected in cells transfected with a plasmid containing a head to tail dimer of HBV DNA (Figure 1a) . To investigate the role of pX under these conditions we constructed the X-KO HBV mutant. This HBV mutant contains a stop codon at position 27 of the X ORF (Ori et al., 1998) , and does not produce pX (con®rmed by Western blotting, data not shown). Cells were transfected with either wt or mutant HBV-DNA and were cisplatin treated in a time course manner, and RNA and protein fractions were extracted. RNA samples were analysed by Northern blotting using an HBV DNA probe. Interestingly, a signi®cant reduction in the steady state level of the HBV mutant transcripts was observed in the cisplatin treated cells (Figure 1b , lanes 4 ± 6). This reduction is speci®c and was not observed with the control GAPDH RNA. To determine the p53 level we analysed the protein extracts of the same transfected cells. As expected Western analysis revealed that upon cisplatin treatment, p53 was speci®cally accumulated, but not the b-tubulin control (Figure 1b , lower panels). Transfected cells either with wild type HBV DNA or a mutant with a stop codon at position 27 of the X gene open reading frame (X-KO HBV), were treated with 2.5 mg/ml cisplatin for the indicated time points before harvesting. RNA and proteins were extracted, separated on formaldehyde-agarose gel and SDS-PAGE, respectively and analysed. 32 P HBV DNA probe was used to detect the known viral transcripts and GAPDH probe to quantify RNA in each lane. For Western analysis anti human p53 (1801+DO-1) and anti b-tubulin (clone no. TUB2.1 Sigma) antibodies were used. The known viral transcripts are indicated by arrows. (c) Cisplatin activates the p21 but not SV40 early promoter in HepG2 cells. Cells were transfected with 2 mg of either p21-luciferase or SV40-luciferase (Promega) reporter plasmids and after 24 h were treated with cisplatin for the indicated time points. Cell extracts were analysed for luciferase activity. With each of the reporter plasmids the activity in the untreated cells was taken as 100% for calculation of fold of activation The fact that p53 was also accumulated in the wt HBV transfected cells, that show only a mild reduction in the RNA level, strongly argues for speci®c response of the HBV mutant. Furthermore, under similar conditions the expected activation of p21 promoter was obtained, but not a control plasmid (Figure 1c ), suggesting that the accumulated p53 is functional in transcription activation.
Cisplatin represses X-KO HBV transcription
The cisplatin dependent reduction in the steady-state level of X-KO HBV RNA molecules might be the result of either an increased rate of RNA degradation or a decrease in HBV transcription rate. To address this point we measured the HBV RNA half life under dierent conditions, using actinomycin D (Shaul et al., 1981) . Transfected HepG2 cells were either cisplatin treated for 18 h or left untreated before actinomycin D was added to block RNA synthesis. RNA was harvested at the indicated time points and analysed by Northern blotting. The cisplatin treated cells, although as expected poorly expressing HBV RNA ( Figure 2 , lanes 1 ± 4), displayed a reduction in RNA level that is not signi®cantly dierent from untreated cells (lanes 5 ± 8). Thus, the reduction in the HBV RNA level under cisplatin treatment is likely to be due to transcription repression and not to enhanced RNA degradation. Cisplatin does not repress X-KO HBV transcription in Huh7 cells that bear a mutated p53 gene
To investigate the molecular mechanisms of genotoxic stress dependent HBV transcription repression, we used the Huh7 dierentiated hepatocellular cell line, which harbors a mutated p53 gene (Bressac et al., 1990) . These cells show HBV RNA production only when transfected with HBV but not with a control DNA (Figure 3a) . Interestingly, and in contrast to the HepG2 cells, no transcription repression was noticed upon treating the X-KO HBV transfected cells with cisplatin up to 24 h (Figure 3b) . However, repression of X-KO HBV transcription in Huh7 cells could be obtained by cotransfection with a very low amount (10 ng) of the wt p53 expression plasmid (Figure 3c ), suggesting that these cells contain all the components required to elicit p53-dependent HBV transcription repression. Furthermore, a p21-luciferase reporter plasmid was employed to show that in contrast to the HepG2 cells, cisplatin does not activate this promoter in Huh7 cells whereas low amounts of the cotransfected p53 plasmid can do so (Figure 3d ). The inability of cisplatin to repress HBV transcription in Huh7 cells, therefore, is clearly due to the absence of wt p53.
Repression of X-KO HBV transcription by cisplatin is blocked by a p53 dominant negative truncated protein
To further substantiate the possibility that the transcription repression of HBV obtained under genotoxic stress is p53 mediated, we employed a plasmid that expresses the production of the Cterminus oligomerization region of p53 (DD-plasmid). This plasmid was previously shown to sustain a p53 speci®c dominant negative activity (Shaulian et al., 1995) . Here again, the transcription of X-KO HBV in HepG2 cells was repressed upon exposing the cells to cisplatin (Figure 4, lanes 1 ± 3) . Interestingly, the cotransfected DD-plasmid induced a signi®cant increase in the level of HBV transcripts in every single tested time point (Figure 4, lanes 4 ± 6) . These results suggest that in the cisplatin treated HepG2 cells, the X-KO HBV transcription repression is mostly mediated by p53 accumulation.
pX abrogates the p53-mediated repression of HBV transcription
The ®nding that cisplatin had a more dramatic eect on X-KO HBV (Figure 1 ) prompted us to investigate the role of pX in this process. Since we found that the eect of pX is more dramatic at early time posttransfection (data not shown), we repeated the experiments but this time the RNA was harvested earlier (35 h). Under these conditions wt HBV was barely aected by cisplatin whereas the X-KO virus was more responsive and displayed sharp reduction in transcription (Figure 5a ,b, compare lanes 4 ± 6 to 10 ± 12). These results illustrate the dierential behavior of the two HBV DNA genomes and substantiate the possible role of pX in both supporting HBV transcription and abrogating the p53-mediated repression eect. These ®ndings were also con®rmed by cotransfection experiments. When the X-KO HBV plasmid was cotransfected together with an Xexpressor plasmid (SV 2 -X), an increase in the level of HBV transcription was obtained, which was only partially aected by cisplatin (Figure 5b , compare lanes 4 ± 6 to 7 ± 9). Western analysis revealed that cisplatin treatment was eective in inducing the accumulation of the endogenous p53 level (Figure 5b lower panels). Therefore, we concluded that pX assures ecient HBV transcription under genotoxic stress by antagonizing the negative eect of p53 on HBV gene expression.
p73 the recent p53 homologue activates HBV transcription p73 is a recent member of the p53 family, with similar transcriptional activation, DNA binding, and oligomerization domains (Kaghad et al., 1997) . Functionally, both p53 and p73 can induce apoptosis and transcription from promoters containing a p53/p73-response element (Jost et al., 1997; Kaghad et al., 1997) , raising the possibility that this protein might bind HBV enhancer containing a p53 binding site (Ori et al., 1998) . To investigate the eect of p73 on HBV transcription, HepG2 cells were cotransfected with either p53 or p73. Interestingly, unlike p53 that repressed HBV transcription (Figure 6a , lane 2), p73 activated it to a certain level (Figure 6, lane 3) . To substantiate this point we repeated the experiment by cotransfecting increasing amounts of p73 plasmid in the range of ng DNA, stopping before reaching squelching conditions. Clearly, p73 activates HBV Figure 4 A dominant negative p53 plasmid recovers HBV transcription under genotoxic stress. HepG2 cells were transfected with a plasmid that harbors a dimer of X-KO HBV DNA either alone (lanes 1 ± 3) or together with 7 mg DD-p53 plasmid (lanes 4 ± 6) that expresses the production of p53 truncated dominant negative protein (Shaulian et al., 1995) . Cells were cisplatin treated for the indicated time (hours) and extracted according to the protocol described in Figure 1 transcription in a dose-dependent manner (Figure 6b) . Thus, unlike p53, p73 plays a positive role in regulating the HBV enhancers/promoters activity.
Discussion
In this study we report a dramatic reduction in the HBV RNA level under genotoxic stress in the absence of an intact X open reading frame. Genotoxic drugs induce either cell-cycle arrest or apoptosis. Although not directly measured, we do not think that the observed reduction in HBV transcription in response to genotoxic drug treatment, is the result of apoptosis. First, cells were cisplatin treated for relatively short periods of time (from 12 to 24 h), which are not long enough to induce eective apoptosis and/or cell cycle arrest. Second, the level of total extracted RNA (data not shown) and GAPDH control mRNA were not reduced upon cisplatin treatment. Also, no reduction in b-tubulin protein along the dierent treatments was observed, ruling out a reduction in cell number due to cell death. Third, despite our attempts we did not see any changes in cell morphology along cisplatin treatments (data not shown).
Cells exposed to various types of stress, in particular those that lead to DNA damage, exhibit an increase in the cellular level of p53 (reviewed in Haner and Oren 1995; Ko and Prives 1996; Gottlieb and Oren 1996) . Accordingly, we show that the cisplatin mediated HBV transcription repression is mostly p53 dependent. First, there is good correlation between p53 level and repression of HBV transcription; second, HBV transcription repression was not detected in a cell line that contains a mutant p53 gene; third, a cotransfected p53 dominant negative mutant eliminated the cisplatindependent repression eect on HBV transcription. Furthermore, the obtained repression is abrogated by a cotransfected papiloma E6 gene (data not shown) whose product selectively enhances p53 degradation (Schener et al., 1990) . Collectively, these data strongly suggest that p53 is an important upstream eector in repressing HBV transcription.
An intimate and unusual interaction between p53 and the HBV genome has been reported. Previously we reported that p53 binds to the 5' portion of the HBV enhancer in a sequence speci®c manner and represses its activity (Ori et al., 1998) . This was an unexpected ®nding, since DNA-bound p53 is known to stimulate transcription. Although the underlying repression mechanism is unknown, it might repress to a certain level HBV transcription in p53 pro®cient cells. The obtained dramatic increase in HBV transcription by the p53 dominant negative mutant (Figure 4 ) is in accordance with this possibility. The p53-mediated repression activity is an intrinsic behavior of the HBV enhancer and depends on an intact enhancer EP element (Ori et al., 1998) . The EP-DNA element of the HBV enhancer binds RFX1 and c-Abl (Agami and Shaul 1998; Dikstein et al., 1992; Siegrist et al., 1993) . Interestingly, genotoxic drugs were reported to induce interaction of the c-Abl tyrosine kinase and p53 (Yuan et al., 1996) , therefore, HBV enhancer is designed to eectively respond to genotoxic stress. This is not so puzzling considering the fact that the liver cells, the HBV natural host cells, are often exposed to toxic agents absorbed via the digestive tract. Furthermore, at least in HBV transgenic mouse model, chronic active hepatitis displays greatly increased hepatic oxidative DNA damage (Hagen et al., 1994) . Thus, the p53 HBV DNA interplay illuminates a molecular mechanism of virus-host adaptation.
Our data also suggest that an autoregulatory loop regulates X gene transcription. The X gene promoter is positioned next to the viral enhancer that binds p53 (Ori et al., 1998) , therefore, the level of pX production depends on the level of p53, but p53 eect on the enhancer is pX dependent. This pX mode of action is compatible with its role ensuring optimal viral gene expression under a wide range of physiological conditions. A similar scenario was observed with papiloma viruses. Treatment with genotoxic agent led to strong repression of E6/E7 expression in HPV16-and HPV18-positive cervical carcinoma cell lines (Butz et al., 1996) possibly via p53. However, E6 in turn enhances p53 degradation (Schener et al., 1990) .
In contrast to p53, the p73 protein level is not elevated by genotoxic stresses (Kaghad et al., 1997) , therefore it is unlikely that p73 is responsible for the observed HBV transcription repression under these conditions. Given the facts that HBV genome contains a functional p53 binding site (Ori et al., 1998) , and that p73 binds DNA with the same sequence speci®city (Zhu et al., 1998) , it is not surprising that p73 also regulates HBV transcription. Remarkably, we found that p73 activates rather than represses HBV gene expression. To our knowledge this is the ®rst example of these two proteins playing opposite roles. As in the dierentiated liver cells the level of p53 is likely to be low, it is not too speculative to assume that under normal conditions p73 is the more accessible factor to interact and hence to support HBV transcription. This trend will be shifted to the opposite direction while exposing the cells to conditions that give rise to p53 accumulation, such as genotoxic stress. Thus, the mode of interplay between p73, p53 and the HBV pX protein described here seems to be designed to assure not only HBV transcription activation but also repression, the latter possibly activated under unfavorable conditions for viral transcription and replication. This might explain how HBV sustains a long term and persistent infection in concert with the host-cell physiology without inducing noticeable cytophatic eects.
We also report here that physiological levels of pX that is expressed from the HBV genome and antagonizes the p53 dependent HBV transcription repression. The relationship between p53 and pX was investigated by a number of groups under dierent arti®cial systems (Chirillo et al., 1997; Feitelson et al., 1993; Lin et al., 1997b; Schaefer et al., 1998; Takada et al., 1996; Truant et al., 1995; Ueda et al., 1995; Wang et al., 1994) . Dierent models were proposed to explain the antagonistic eect observed between these two proteins. For example, some suggested that pX changes the p53 compartmentalization by localizing it predominantly in the cytoplasm (Ueda et al., 1995; Takada et al., 1997) , while others proposed physical and interfering interaction between the two proteins (Wang et al., 1994; Lin et al., 1997a; Truant et al., 1995) . However, the activation domain of p53 when fused to the Gal4 DNA-binding domain, is coactivated and not inhibited by pX (Haviv et al., 1998a) . Therefore, the site of interference between the two proteins localized outside the p53 activation domain. Furthermore, the p53 activation domain targets TAFs in transcription machinery (Thut et al., 1995; Farmer et al., 1996a) , whereas pX targets TFIIB and polymerase II (Cheong et al., 1995; Haviv et al., 1998b; Lin et al., 1997a) . The mechanism of transcription repression by p53 is unknown, but since it can be alleviated by coexpression of the TAF proteins (Farmer et al., 1996a) , it was suggested that p53 represses transcription via TAF sequestration (Farmer et al., 1996b; Liu and Berk 1995) . In contrast, pX supports transcription in the absence of TAFs both in vitro and in vivo (Haviv et al., 1998a; 1996) . Therefore, pX is expected to activate transcription under conditions whereby TAFs are inactive due to their sequestration by p53. This likely possibility suggests a novel way of functional inactivation of p53 by pX that does not require their physical interaction.
HBV is an important risk factor of chronic liver diseases, including HCC. It has been speculated that pX, the HBV regulatory protein, is a major player in this process. Functional inactivation of p53 by pX was demonstrated so far only under arti®cial contexts, i.e., overproduction of either pX or p53, and therefore their relevance remained questionable. We show that physiologically activated p53 represses HBV transcription. Furthermore, this repression is abrogated by physiological levels of pX that is produced in the context of an intact HBV genome. Thus, it is not too speculative to propose that in the natural route of HBV infection hepatocytes experience p53 functional inactivation and therefore become more prone to transformation.
Materials and methods
Cell culture, DNA transfection and treatments
HepG2 and Huh7 cells were cultured in Dulbecco modi®ed Eagle's minimal essential medium (GIBCO Laboratories) containing 100 U of penicillin and 100 mg of streptomycin per ml, supplemented with 8% fetal bovine serum. Transfection was carried out by the CaPi method as previously described . Each transfection reaction contained a constant amount of 25 mg DNA per 10 cm dish, consisting of 15 mg HBV plasmid. The latter contains two tandem copies of HBV full-length DNA (subtype adw), ligated via the unique EcoR1 site. The HBV mutant (X-KO HBV) was constructed by generating a stop codon at position 27 of the X gene (Ori et al., 1998) . WT HBV or X-KO HBV dimers were inserted into pGEM-3Z in a head to tail orientation, which con®rmed by restriction enzyme analysis. For cisplatin treatment, HepG2 and Huh7 cells were treated with 2.5 mg/ ml cisplatin about 26 h after transfection. For analysis of HBV RNA half-life, HepG2 cells were treated with 2.5 mg/ml cisplatin for 18 h and then 5 mg/ml Actinomycin D (A4262, Sigma) was added for the indicated time points.
RNA analysis
Northern analysis was carried out by agarose-formaldehyde (1%) method according to published protocols (Sambrook et al., 1989) . RNA quality and quantity was monitored by UVabsorption and by ethidium-bromide staining. Radioactive probes were prepared by random priming protocol, using either a full length HBV DNA or GAPDH cDNA templates and 32 PadCTP (Amersham, 3000 Ci/mmole). Total RNA was extracted from transfected cells at various time points after transfection by TRI REAGENT (MRC, INC.). The RNA samples were treated with RNase free DNaseI (Boehringer) for 15 min at 378C and stored until used. For Northern blot analysis 25 mg of total RNA per sample was separated on 1% formalehyde-agarose gel and blotted to a Hybond-N nylon membrane (Amersham). Membranes were prehybridized and hybridized according to the manufacturer instructions. About 10 6 c.p.m. (10 ng DNA) labeled either 3.2 Kb HBV or 1.3 Kb GAPDH DNA fragments was used per 1 ml hybridization buer. After hybridization the membrane was washed for 60 min at 658C in a 0.1% SSC 0.1% SDS buer and exposed to an X-ray ®lm for autoradiography. Densitometry was performed by a Fujix Bas 2500 phosphrimager (Fuji).
Protein analysis
Proteins were extracted form cells by TRI-REAGENT (MRC, INC.) according to the manufacturer's instructions and solubilized for 30 min at 508C in Laemmli sample buer containing 4 M urea. Soluble proteins were boiled for 10 min and subsequently fractionated on 10% SDS-polyacrylamide gel. For Western blot analysis, gels were electroblotted to a nitrocellulose membrane for 1 h at 200 mA. Membrane ®lters were stained after blotting by Ponceau S, soaked for 2 h at RT in a blocking solution [Phosphate buer saline (PBS) containing 4% w/v dried non-fat-milk powder and 0.01% v/v tween-20 (Sigma)]. All further incubation steps were performed in the same solution. Filters were incubated for 1 ± 2 h at RT in the presence of either anti human p53 (1801+DO-1) or anti b-tubulin (clone no. TUB2.1, Sigma) antibodies, and washed three times with PBS+0.01% tween-20. Protein A horse radish peroxidase (HRP) conjugated (ICN laboratories) was added (diluted 1 : 10 000 in blocking solution) and incubation allowed to proceed for an additional hour followed by three rounds of washes. Antibody-antigen complexes were visualized by the ECL chemiluminescent detection system (Pierce) according to the manufacturer instructions, on an X-ray ®lm.
